Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $81.36M | $-142.62M | $-1.12 |
| 2024 | $70.84M | $-157.85M | $-1.62 |
| 2023 | $69.56M | $-240.05M | $-2.94 |
| 2022 | $209.91M | $-157.13M | $-1.99 |
| 2021 | $33.92M | $-230.03M | $-3.00 |
Social Signal Score
Earnings
Tue, Nov 10(in 3 months)
Consensus estimate $-0.21 per share
Typical surprise +23.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.11 vs $-0.22beat
- Mon, May 4$-0.21 vs $-0.19miss
- Tue, Mar 10$-0.04 vs $-0.32beat
- Mon, Nov 10$-0.30 vs $-0.40beat
- Tue, Aug 12$-0.50 vs $-0.36miss
- Wed, May 14$-0.36 vs $-0.38beat
Estimates and results for ADCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ADCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·2d ago·Positive
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·2d ago·Negative
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
View source ↗